Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 300 for “"payers"”.
-
Transfer pricing model for tax payers and tax administrators /
… This model can be applied by the tax payers who needs to determine the arm’s length transfer prices in practise (e.g. for sale of goods, provision of services, loans and other inter-company transactions) and for tax administrators who are controlling the compliance of transfer prices …
-
Are Risk-takers Dividend Payers? CEO Compensation and its Impact on Dividend Decision
Both dividend policy and CEO risk aversion have been subjects of tremendous research over the past 30 years. The current gap is how both topics are sporadically considered in tandem. We provide a solution to this by analyzing dividend changes in the context of CEO risk-taking incentives. Our …
-
Comparison of the approval process between private and public payers in hematopoietic stem cell transplantation
Objectives: The increased use of hematopoietic stem cell transplant (HSCT) for its potentially curative properties has led to studies examining the quality of care that is currently received. More specifically, research examining the timeliness aspect of quality of care is being addressed. This …
-
A Time Study of Audiological Practice Patterns and the Impact of Reimbursement Changes from Third Part Payers
The primary objective of the project was to survey audiologists in clinical practice setting to determine the amount of time taken to perform various audiologic tests using Current Procedural Terminology, (CPT) codes to define these tests and if these CPT codes were felt to be adequate. …
-
Proposals for Updating the Canadian Patented Medicine Prices Review Board Pharmaceutical Budget Impact Analysis Guidelines for New Drug Submissions to Public and Private Payers
… of expert opinions, data extrapolated from the payers’ database, scenario analysis, and dynamic population. Thirty percent of the recommendations, such as off-label indications in the base-case scenario, indirect costs, and cost transfers from other jurisdictions, were not supported by …
-
Comparing how Medicare Part D sponsors and commercial third-party payers calculate prescription reimbursement rates and the subsequent impact on the financial viability of independent pharmacies in Texas
… Part D sponsors and commercial third-party payers, resulting in decreased gross margins for independent pharmacies; however, reports are inconclusive regarding which payer more greatly affects independent pharmacies’ financial viability. Using 2006-2009 prescription claims data collected by …
-
Profitability Premium Puzzle and Investors' Behavioral Mistakes
… into two groups: dividend and non-dividend payers and hypothesize that profitability premium may only exist among the firms with unforeseeable future cash flows, i.e., non-dividend payers. As expected, my empirical results support that profitability premium only exists among non-dividend …
-
Institutional Investor Heterogeneity and the Information Content of Dividends
… effect is stronger and concentrated in bottom payers. Furthermore, the change of holdings owned by institutional investors with different incentive to monitor a firm's governance has distinct effects on the decline of information content across top and bottom payers. Our results indicate that …
-
Dividend Policy, Stock Liquidity and Stock Price Informativeness
… We show that, on average, stocks of dividend payers have significantly lower bid–ask spread and a lower illiquidity ratio than their counterparts of non-dividend payers. We also find that stocks of high-dividend payers are more liquid than those of firms that pay low or no dividends. These …
-
Two Essays on Forced CEO Turnover During Envy Merger Waves, and Dividends
… towards dividend paying-firms. We find that payers outperform non-payers during the financial crisis. Further, the results document that non-payers with buybacks outperform non-payers with no buybacks. This indicates that payouts can function as an insurance mechanism for investors, and this …
-
Information in Financial Markets
… of information asymmetry in alleviating dividend payers’ seasoned equity offering (SEO) announcement returns, the leading behavior of equity analysts who collect and process information, and the pricing of productivity-related information. More specifically, Chapter 1 studies whether the market …
-
Behaviour in a Canadian Multi-payer, Multi-provider Health Care Market: The Case of the Physiotherapy Market in Ontario
… involving the interaction of public and private payers and for-profit (FP) and not-for-profit (NFP) providers; the influence of health professionals on market structure; and the role of foreign investment. A case study was used, the Ontario physiotherapy market in 2003-2005, with its complex mix …
-
A Stakeholder-Informed Conceptual Framework for Evaluating Genomics in Precision Oncology
… in precision oncology with an emphasis on how US payers conceptualize and prioritize elements of value. This research aims to address gaps in understanding payer perspectives and proposes a stakeholder-informed framework for evaluating genomic testing in oncology. To achieve this aim, the …
-
Didesnio tarifo mokestis Lietuvos apmokestinimo sistemoje /
… legal regulation provided by laws for tax payers in different situations does not constitute discrimination but is justified in pursuit of public welfare and the implementation of specific economic and social goals. The thesis highlights the necessity of tax collection for the …
-
Payer Perspectives On Preemptive Pharmacogenetic Testing
… pharmacogenetic testing of third-party payers. Methods: A qualitative study utilizing a blended inductive and directed approach was conducted. A screener survey determined interview eligibility as well as demographic data. Semi-structured interviews were conducted with payers from …
-
Assessing the Impact of Health Economics and Outcomes Research Evidence on Reimbursement Decisions in the United States
… types of HEOR evidence are important to U.S. payers and tested these hypotheses in a survey of HEOR decision-makers in pharmaceutical companies and formulary decision-makers for payer organizations. Results: Previous studies suggest a growing importance of HEOR evidence in U.S. reimbursement …
-
Exploring the uptake of value-based formulary strategies and their application to specialty drugs
… increase drug adherence, and be cost neutral for payers when applied to many traditional drugs, such as antihypertensive and antihyperlipidemic therapies. It is unclear whether these same outcomes could be achieved if VBF strategies were applied to other drugs, such as specialty drugs. Specialty …
-
CORPORATE MORAL HAZARD IN U.S. HEALTH INSURANCE: CHURN AND DENIAL RATES
… misalignment, and may shift costs between payers. I test whether commercial payers, anticipating disenrollment, tighten adjudication in ways consistent with what I define in this context as corporate moral hazard. If so, denial rates should rise just before the switch to Medicare. …
-
Market potential for pork products with embedded environmental attributes: an experimental approach
… attributes. The average premium paid by premium payers under both measures ranged from 1.62 to 2.23 for the package with all three embedded environmental attributes. Statistical methods were used to examine whether there were differences in premiums with differing levels of embedded environmental …
-
Value-based real option analysis to support early-stage drug development
… analysis based a Markov model assuming a US payers’ willingness to pay (WTP, λ) of $50,000 per quality-adjusted life year (QALY) and payers’ discount rate (rd) of 3%. The drug candidate’s target product profile (TPP) was based on clinician reports on meaningful health improvements. 2. ROA via …
Page 1 of 15